Raymond Thertulien is a Hematology physician affiliated with Novant Health. OpenAlex indexes 56 publications with 1,967 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
125 Queens Rd Ste 610
Charlotte, NC 282043580
Telephone
980-302-6600Provider last certified this registry record 11 Jul 2024.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202541 payments$47,309openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year202517 payments$17,242openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
37.3%Thalidomide Analog29.9%Revlimid69%Pomalyst20%Lenalidomide11%Part D<11 patientsProteasome Inhibitor5.8%Ninlaro100%Part D<11 patients+ 1 more class in this area
Anti-infectives
19.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor13.1%Valacyclovir100%Part D≥28 patientsShort-acting sulfonamides6.5%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsMetabolism & gastrointestinal
13%Proton pump inhibitor4.9%Omeprazole51%Pantoprazole Sodium49%Part D<11 patientsPotassium supplement4.1%Potassium Chloride100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- COVID 19 Infection in Autologous Stem Cell Transplant (ASCT) Recipients: a Single Institution Observational Cohort
Biology of Blood and Marrow Transplantation
2023 - Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer
Journal of Thoracic Oncology
2011 - Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies
Cancer Chemotherapy and Pharmacology
2011
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”